Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.4K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.4K
Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

1.7K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.7K
Bacterial Toxins01:12

Bacterial Toxins

54
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
54
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.2K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.2K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

723
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
723
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occupation and education level in functional motor disorders.

Parkinsonism & related disorders·2026
Same author

Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?

Journal of Parkinson's disease·2026
Same author

Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson's disease: A 3-year single-center study.

Journal of Parkinson's disease·2026
Same author

Teaching Video NeuroImage: Tardive Blepharoclonus.

Neurology·2026
Same author

Cognitive and motor reserve in Parkinson's disease: Two sides of the same coin?

Journal of neuropsychology·2026
Same author

Predictive value of cerebrospinal fluid Alzheimer's disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson's disease.

Brain communications·2026

Related Experiment Video

Updated: Apr 5, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.8K

Clinical differences between botulinum neurotoxin type A and B.

Anna Rita Bentivoglio1, Alessandra Del Grande1, Martina Petracca1

  • 1Institute of Neurology, Università Cattolica del Sacro Cuore, Roma, Italy.

Toxicon : Official Journal of the International Society on Toxinology
|August 12, 2015
PubMed
Summary

Botulinum neurotoxin A (BoNT/A) and B (BoNT/B) offer therapeutic benefits, but clinical data comparing their safety and efficacy is limited. BoNT/B may have shorter efficacy and higher immunogenicity than BoNT/A for muscular conditions.

Keywords:
AbobotulinumBoNT/ABoNT/BBotulinum toxinIncobotulinumOnabotulinumRimabotulinumTherapyTreatment

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.7K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

9.0K

Related Experiment Videos

Last Updated: Apr 5, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.7K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

9.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Biotechnology

Background:

  • Botulinum neurotoxins (BoNTs) are widely used therapeutically, with four types available: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB.
  • While BoNT/A products are approved for various indications, comparative data on the safety and efficacy of different BoNT serotypes is scarce.

Purpose of the Study:

  • To review and synthesize existing literature comparing the clinical safety and efficacy of botulinum neurotoxin A (BoNT/A) and botulinum neurotoxin B (BoNT/B).
  • To highlight the differences in product characteristics and clinical outcomes between BoNT/A and BoNT/B.

Main Methods:

  • Literature review of comparative studies on BoNT/A and BoNT/B.
  • Analysis of data from small sample reports and limited evidence-based medicine studies.

Main Results:

  • BoNT/A and BoNT/B show comparable efficacy in some applications, but dose ratios vary.
  • BoNT/B may be associated with more painful injections, shorter efficacy in muscular conditions, and higher immunogenicity compared to BoNT/A.
  • Autonomic side effects are more frequent with BoNT/B, supporting its use in indications like sialorrhea and hyperhidrosis.

Conclusions:

  • Comparative data on BoNT products is limited, necessitating careful consideration of individual product characteristics.
  • While both BoNT/A and BoNT/B are effective, differences in efficacy duration, side effect profiles, and immunogenicity exist.
  • Further high-quality comparative studies are needed to guide optimal therapeutic use of different botulinum neurotoxin serotypes.